Masashi Nabetani

Are you Masashi Nabetani?

Claim your profile

Publications (2)4.17 Total impact

  • Article: Postoperative Bleeding Complications after Gastric Cancer Surgery in Patients Receiving Anticoagulation and/or Antiplatelet Agents.
    Kazuhito Mita, Hideto Ito, Ryo Murabayashi, Kouichirou Sueyoshi, Hideki Asakawa, Masashi Nabetani, Akira Kamasako, Kazuya Koizumi, Takashi Hayashi
    [show abstract] [hide abstract]
    ABSTRACT: Perioperative antithrombotic treatment for gastric cancer patients receiving chronic anticoagulation and/or antiplatelet agents requires an understanding of potential bleeding and thromboembolic risks. However, no study has examined the safety aspects of perioperative antithrombotic treatment during radical gastrectomy. This study sought to evaluate postoperative bleeding and thromboembolic complications after radical gastrectomy in patients undergoing perioperative antithrombotic treatment. The medical records of patient treated by radical gastrectomy from January 2006 to December 2010 were retrospectively reviewed. Those in the thromboprophylaxis group had received one of three regimens of perioperative antithrombotic treatment according to the clinical indications of chronic anticoagulation and/or antiplatelet agents and several published evidence-based recommendations: (1) bridging therapy with unfractionated heparin; (2) continuation of aspirin; or (3) both 1 and 2. multivariate analysis was used to identify risk factors for postoperative bleeding complications after radical gastrectomy. During the study period, 340 patients underwent radical gastrectomy. Of these, 62 patients received perioperative antithrombotic treatment; this thromboprophylaxis group had a significantly higher postoperative bleeding rate (8.1 vs. 0.7 %, P = 0.003). However, other complications, including thromboembolic events, were similar in the two study groups. Multivariate analysis revealed that perioperative antithrombotic treatment was the only independent risk factor of postoperative bleeding complications after radical gastrectomy (odds ratio, 8.53; 95 % confidence interval, 1.47-49.39; P = 0.017). Perioperative antithrombotic treatment is an independent risk factor of postoperative bleeding complications in patients with gastric cancer undergoing radical gastrectomy, although such treatment was effective in preventing postoperative thromboembolic events.
    Annals of Surgical Oncology 07/2012; 19(12):3745-52. · 4.17 Impact Factor
  • Source
    Article: Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study.
    Kazuhito Mita, Hideto Ito, Masato Fukumoto, Ryo Murabayashi, Masashi Nabetani, Kazuya Koizumi, Takashi Hayashi
    [show abstract] [hide abstract]
    ABSTRACT: The aim of this study was to investigate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. A retrospective study was performed on 15 consecutive patients. Gemcitabine was administered intravenously at 1,000 mg/m(2) on days 8 and 15. Oral S-1 (60 mg/m(2) in 2 divided doses) was given daily for the first 2 weeks, followed by 1 week of rest. This 3-week course of treatment was repeated. The primary endpoint was response rate, and the secondary endpoints were overall survival, progression-free survival, and safety. The overall response rate was 26.7%, and the disease control rate was 73.4%. The overall survival was 12.0 months (95% CI, 9.5-14.5 months), and the progression-free survival was 8.0 months (95% CI, 4.3-11.7 months). Adverse events of grade 3 or 4 occurred in 33.3%, and the major grade 3/4 toxicities were anemia (20.0%), leukopenia (13.3%), and anorexia (13.3%). Gemcitabine and S-1 combination chemotherapy is effective and safe in patients with advanced biliary tract cancer.
    Case Reports in Oncology 09/2010; 3(3):498-504.
Browse more researchers